Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026
Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026
Devonian Reports Results of its Annual General and Special Meeting of Shareholders
Devonian Health Group Inc. Reports Financial and Operating Results of its Three and Six Months Ended January 31, 2026
Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects
Devonian Advances Thykamine™ Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls
Devonian reports additional molecular data from MASH liver study
DEVONIAN REPORTS POSITIVE RESULTS IN PULMONARY FIBROSIS STUDY
DEVONIAN APPOINTS DENNIS TURPIN AS CHIEF FINANCIAL OFFICER AND PROVIDES UPDATES ON STOCK OPTIONS GRANT
DEVONIAN ANNOUNCES SHARE CONSOLIDATION IN FURTHER PREPARATION FOR POTENTIAL U.S. LISTING
Devonian Health Group Announces Grant of Stock Options
Devonian Health Group Announces Publication of Landmark Study Highlighting Thykamine™ as a Promising New Anti-Inflammatory Agent
Devonian Health Group Reports its Fourth Quarter and Annual 2025 Financial Results and Appointment of a New Board Member
Devonian Health Group Inc. announces its participation to the ThinkEquity Conference in New York and closing of a Non-Brokered Private Placement of Units
Devonian Provides Corporate Update and Additional Information Regarding its Previously Announced Private Placement
Devonian Announces Closing of a Private Placement of Units
Devonian Health Group Reports Third Quarter 2025 Financial Results
Devonian Appoints New Officers and Announces Grant of Stock Options
Devonian Health Group Announces Reinstatement of Quotation on the TSXV
Devonian Health Group Reports Cease Trade Order
Devonian Reports Delay of Financial Reporting
Devonian Reports Results of its Annual General and Special Meeting of Shareholders
Devonian Announces the Filing of a New Patent Application Relating to the Use of Thykamine™ as an Antifibrotic Agent
Devonian Announces Positive in Vivo Results of Thykamine™ on Gene Expression Associated With Fibrosis
Devonian Reports Positive Results in MASH Liver Study
Devonian Health Group Inc. Reports Superior Anti-Inflammatory Potency of Thykamine™ in Comparative In Vitro Study
Devonian Health Group Reports First Quarter 2025 Financial Results and Grants Stock Options